Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14762600 | 0.86 | ALDH1A1 (0.41) | — | |
| SCHEMBL9367912 | 0.83 | FKBP1A (0.45) | FKBP1AHPGDHTR2CFABP7FABP5 | |
| SCHEMBL7362332 | 0.83 | FKBP1A (0.45) | FKBP1AHPGDHTR2CFABP7FABP5 | |
| SCHEMBL31696756 | 0.82 | MMP2 (0.55) | FKBP1ACYP2C19 | |
| SCHEMBL28975603 | 0.81 | FKBP1A (0.49) | FKBP1ACYP2C19HTR2CFABP7FABP5 | |
| SCHEMBL28975604 | 0.81 | FKBP1A (0.49) | FKBP1ACYP2C19HTR2CFABP7FABP5 | |
| SCHEMBL5203676 | 0.80 | MMP2 (0.39) | HPGDCYP2C19 | |
| SCHEMBL5203668 | 0.80 | MMP2 (0.39) | HPGDCYP2C19 | |
| SCHEMBL10137577 | 0.79 | FKBP1A (0.47) | FKBP1AHPGDCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL994630 | 0.79 | FKBP1A (0.50) | FKBP1AHPGDCYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-6605630-B1 | Active against drug resistant gram positive pathogens | SYNGENTA LIMITED (GB) | 2003-08-12 | — | — | US | disclosed |
| EP-1005468-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010342-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216374-A1 | Antibiotic oxazolidinone derivatives | OXA1L, HRH1, OGDH | FKBP1A 1815/4885HPGD 2311/4885CYP3A4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.